Alpine Global Management LLC Purchases Shares of 1,129 Cencora, Inc. (NYSE:COR)

Alpine Global Management LLC purchased a new stake in Cencora, Inc. (NYSE:COR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,129 shares of the company's stock, valued at approximately $254,000.

Several other large investors have also modified their holdings of the business. J. Safra Sarasin Holding AG acquired a new position in shares of Cencora in the 4th quarter valued at $4,156,000. Stifel Financial Corp grew its holdings in shares of Cencora by 1.1% during the 4th quarter. Stifel Financial Corp now owns 76,861 shares of the company's stock worth $17,284,000 after purchasing an additional 857 shares during the period. TD Waterhouse Canada Inc. raised its holdings in Cencora by 1.5% in the fourth quarter. TD Waterhouse Canada Inc. now owns 79,853 shares of the company's stock valued at $17,941,000 after buying an additional 1,192 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Cencora by 124.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,115 shares of the company's stock worth $2,048,000 after acquiring an additional 5,047 shares in the last quarter. Finally, Transce3nd LLC acquired a new position in shares of Cencora during the 4th quarter valued at $122,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Performance

Shares of COR traded up $1.49 during trading hours on Monday, reaching $287.39. 282,212 shares of the company's stock traded hands, compared to its average volume of 1,517,999. The firm has a market capitalization of $55.73 billion, a price-to-earnings ratio of 40.85, a P/E/G ratio of 1.31 and a beta of 0.55. The business's fifty day simple moving average is $268.09 and its two-hundred day simple moving average is $249.54. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $296.65. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.77%. The ex-dividend date was Friday, February 14th. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Analyst Upgrades and Downgrades

COR has been the topic of a number of recent analyst reports. Bank of America boosted their price objective on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Wells Fargo & Company boosted their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. JPMorgan Chase & Co. increased their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Evercore ISI increased their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Finally, StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Cencora has a consensus rating of "Moderate Buy" and an average target price of $284.55.

Insider Buying and Selling at Cencora

In related news, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares in the company, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the transaction, the executive vice president now owns 14,665 shares in the company, valued at approximately $3,934,326.20. This trade represents a 21.96 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 50,223 shares of company stock valued at $13,580,967. 10.80% of the stock is owned by insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.